Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers

Trial Profile

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tebipenem pivoxil (Primary) ; Tebipenem pivoxil
  • Indications Gram-negative infections; Haemophilus infections; Streptococcal infections; Urinary tract infections
  • Focus Adverse reactions; First in man
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 01 Jul 2019 Results assessing the safety,pharmacokinetics and food effect of Tebipenem pivoxil hydrobromide published in the Antimicrobial Agents and Chemotherapy
    • 17 Jun 2019 According to a Spero Therapeutics media release, data from this trial will be presented at the American Society of Microbiology (ASM) Microbe 2019 Conference.
    • 16 Apr 2019 Results assessing population PK modelling of the human Phase I to select the clinical dose for Phase III, clinical data presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top